No phaseNot yet recruiting
REmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH. (READY-ICH)
Efficacy and Safety of an Early Intensive Blood Pressure-Lowering Strategy Using Remifentanil and Dexmedetomidine in Patients With Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Superiority, Randomized Controlled Trial
- Sponsor
- The Third Affiliated Hospital of Southern Medical University (Government)
- Enrolment
- 1,116 planned
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Remifentanil and Dexmedetomidine; Guideline standard care
- Ages
- adults, older adults
- Registry
- NCT07695220
Full record on ClinicalTrials.gov
From the registry
Intracerebral hemorrhage (ICH) remains the most devastating subtype of stroke, with a case fatality rate of approximately 40% at one months post-onset, imposing a particularly heavy medical and economic burden on low- and middle-income countries. Studies have shown that poor prognosis in ICH patients is associated with acute blood pressure elevation and hematoma expansion after onset. Blood pressure control during the acute phase is considered a potentially key therapeutic strategy for improving outcomes in ICH patients; however, no clinical study has yet demonstrated a clear advantage of any specific antihypertensive agent or combination. Previous researchers have confirmed that the combined use of remifentanil and dexmedetomidine, while providing effective analgesia, sedation, and anti-sympathetic effects, could reduce dramatic fluctuations in blood pressure and heart rate, thereby facilitating more stable blood pressure reduction and potentially further improving functional outcomes in ICH patients. The investigators plan to conduct a multicenter, prospective, randomized…
Primary outcomes
- The modified Rankin Scale score at 90 days post-treatment
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered